(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 11.48% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 35.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.15%.
Ani Pharmaceuticals's revenue in 2026 is $826,880,000.On average, 9 Wall Street analysts forecast ANIP's revenue for 2026 to be $22,144,579,178, with the lowest ANIP revenue forecast at $20,103,941,692, and the highest ANIP revenue forecast at $25,210,253,904. On average, 7 Wall Street analysts forecast ANIP's revenue for 2027 to be $24,783,342,296, with the lowest ANIP revenue forecast at $21,163,131,860, and the highest ANIP revenue forecast at $28,513,201,608.
In 2028, ANIP is forecast to generate $25,390,006,160 in revenue, with the lowest revenue forecast at $21,775,188,292 and the highest revenue forecast at $29,142,334,504.